Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 0.82 |
| ▸ | EGLN2 | Q96KS0 | 18/20 | 0.74 |
| ▸ | THRA | P10827 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270016 | 0.92 | EGLN1 (0.76) | EGLN1EGLN2THRATHRB | |
| SCHEMBL29956293 | 0.91 | EGLN1 (0.77) | EGLN1EGLN2THRATHRB | |
| SCHEMBL23269740 | 0.91 | EGLN1 (0.77) | EGLN1EGLN2THRATHRB | |
| SCHEMBL22958806 | 0.90 | EGLN1 (0.84) | EGLN1EGLN2 | |
| SCHEMBL523124 | 0.90 | EGLN1 (1.00) | EGLN1EGLN2THRATHRB | |
| SCHEMBL29726484 | 0.90 | EGLN1 (1.00) | EGLN1EGLN2THRATHRB | |
| SCHEMBL23269742 | 0.88 | EGLN1 (0.76) | EGLN1EGLN2 | |
| SCHEMBL15268582 | 0.88 | EGLN2 (0.83) | EGLN1EGLN2 | |
| SCHEMBL522758 | 0.86 | EGLN1 (0.84) | EGLN1EGLN2THRATHRB | |
| SCHEMBL15268494 | 0.85 | EGLN2 (1.00) | EGLN1EGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340532-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICALS INT GMBH (CH) | 2022-10-27 | — | — | US | disclosed |
| EP-4010318-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2022-06-15 | — | — | EP | disclosed |
| CN-112679431-A | Method for preparing isoquinolone compound | 上海迪赛诺化学制药有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-112679430-A | Method for preparing isoquinolone compound | 上海迪赛诺化学制药有限公司 | 2021-04-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340532-A1 | PROCESSES FOR THE PREPARATION OF ROXADUSTAT AND INTERMEDIATES THEREOF | CYP2B6, CBR3, CYP3A4 | EGLN1 342/4885EGLN2 275/4885THRA 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.